text: Areteia Therapeutics is currently conducting three global Phase III clinical trials of dexpramipexole in eosinophil-associated asthma as listed below.
  EXHALE-2: a global Phase III clinical trial to evaluate the efficacy and safety of dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma, is currently recruiting people ≥12 years old with a documented physician diagnosis of asthma who require medium to high dose inhaled corticosteroids with at least one other controller medicine and a history of asthma exacerbations. The study will assess the effects of two different doses of dexpramipexole on exacerbation rates and lung function.
  EXHALE-3: a global Phase III clinical trial to evaluate the efficacy and safety of dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma, is currently recruiting people ≥12 years old with a documented physician diagnosis of asthma who require medium to high dose inhaled corticosteroids with at least one other controller medicine and a history of asthma exacerbations. The study will assess the effects of two different doses of dexpramipexole on exacerbation rates and lung function.
  EXHALE-4: a global Phase III clinical trial to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma, is currently recruiting people ≥12 years old with a documented physician diagnosis of asthma who require treatment with at least low-dose inhaled corticosteroids and one other controller medicine. The study will assess improvements in lung function, asthma control, and quality of life.